Statistics from Altmetric.com
Cardiogenic shock (CS) is a physiological state in which inadequate tissue perfusion results from cardiac dysfunction, most commonly following acute myocardial infarction. Non-ischaemic causes include myocarditis, end-stage cardiomyopathy or sustained arrhythmias.
The use of reperfusion therapy has substantially reduced 30-day mortality in acute ST-segment elevation myocardial infarction (STEMI) patients.w1–w3 Currently, the optimal reperfusion therapy is timely primary percutaneous coronary intervention (PCI). The improvement in clinical outcome has been mostly observed in STEMI patients without cardiogenic shock. Despite reperfusion therapy, approximately 6–10% of STEMI patients develop cardiogenic shock during initial hospitalisation.1 ,2 w4 The large multicentre Should we Emergently Revascularise Occluded Coronaries for Cardiogenic Shock? (SHOCK) trial and registry demonstrated that early revascularisation, including PCI or coronary artery bypass grafting, in cardiogenic shock patients improves clinical outcome, but the overall 6-month mortality of cardiogenic shock patients remained 50%3 in accordance with other reports.1 w4 Despite reperfusion by primary PCI, cardiogenic shock remains the leading cause of death for hospitalised STEMI patients.1 w5
Cardiogenic shock after STEMI is mostly a consequence of decreased myocardial contractility due to the infarction, resulting in a cascade of decreased cardiac output, hypotension and decreased coronary blood flow (CBF), which will further reduce contractility and cardiac output. This vicious circle may not only lead to further myocardial ischaemia, but also to diminished organ perfusion and may ultimately result in multiple organ failure and death. Additional aggravation of the downward spiral is caused by a systemic inflammatory response and excess nitric oxide synthesis induced by the myocardial infarction, which further induces vasodilatation.2
Clinically, cardiogenic shock is characterised by hypotension and defined by a systolic blood pressure of less …
Competing interest In compliance with EBAC/EACCME guidelines, all authors participating in Education in Heart have disclosed potential conflicts of interest that might cause a bias in the article. JPSH received honoraria/speaking fees and an unrestricted research grant from Abiomed Europe GmbH (Aachen, Germany). DMO has no conflicts of interest to declare.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.